10x Genomics에 대한 매도 수량은 투자자에게 10x Genomics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

10x Genomics (NASDAQ:TXG) 주식, 공매도 수량 보고

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Equities

News

Markets

ARKW

BEAM

GTLB

목요일, 캐시 우드의 아크 인베스트(Ark Invest)가 자율주행 택시 부문에서 테슬라(NASDAQ:TSLA)의 잠재력에 대한 최근 낙관적인 전망에도 불구하고 이 회사의 지분을 축소하는 중요한 움직임을 보였다.

캐시 우드의 아크 인베스트는 긍정적인 자율주행 전망에도 $800만 테슬라 주식 매도

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

NTLA

TDOC

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:ROKU)와 코인베이스 글로벌(NASDAQ:COIN)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래

아크 인베스트는 로쿠 $730만의 주식을 매수, 비트코인 하락에 코인베이스 주식을 매각

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

S&P/TSX GlbMn US

S&P/TSX Global Gold Index (USD)

S&P/TSX Global Gold Index (USD) (TR)

Guidance

GMED

Globus Medical Sees FY24 Revenue $2.49B-$2.50B Vs $2.481B Est.; Adj. Diluted EPS $2.90-$3.00 Vs $2.85 Est.

WIIM

Limbach Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) affirms FY2024 Adj EPS guidance from $1.50-1.62 to $1.50-1.62 vs $1.49 analyst estimate..

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand expects FY 2024 Net sales Y/Y increase of low single digits; Adj. EBITDA: $385M-$405M; Adj. Diluted EPS: $1.50-$1.62  VS Est. 1.49

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.20 by 16.67 percent. This is a 19.08 percent decrease over earnings of $1.73 per share from the same period last year. The company reported quarterly sales of $513.54 million which missed the analyst consensus estimate of $542.84 million by 5.40 percent. This is a 0.37 percent increase over sales of $511.65 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Northern Oil & Gas Q3 Adj $1.40 Beats $1.20 Estimate, Sales $513.54M Miss $542.84M Estimate

TMCI

Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

BBAI

BigBear.ai Affirms 2024 Revenue Guidance $165M-$180M

BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $41.505 million which missed the analyst consensus estimate of $46.030 million by 9.83 percent. This is a 22.12 percent increase over sales of $33.988 million the same period last year.

BigBear.ai Hldgs Q3 2024 GAAP EPS $(0.05) Beats $(0.07) Estimate, Sales $41.505M Miss $46.030M Estimate

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.65 by 27.69 percent. The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million by 3.61 percent. This is a 63.10 percent increase over sales of $383.64 million the same period last year.

Globus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate

B&G Foods shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 net sales guidance below estimates.

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.
Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.
The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.

Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.14 per share. The company reported quarterly sales of $37.640 million which missed the analyst consensus estimate of $42.000 million by 10.38 percent. This is a 649.35 percent increase over sales of $5.023 million the same period last year.

GIFI

Gulf Island Fabrication Q3 2024 GAAP EPS $0.14, Sales $37.640M Miss $42.000M Estimate

Ternium Q3 2024 EPADS $0.16, Sales $4.480B Beat $4.446B Estimate

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.

Biotech

General

PSTX

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

QLYS

Qualys Expects Q4 Adj EPS Of $1.28 - $1.38 (Est $1.28), Revenues Of $154.5M - $157.5M (Est $154.059M)

MGNX

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) affirms FY2024 Adj EPS guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 analyst estimate. Affirms FY2024 sales outlook from $425.00 million-435.00 million to $425.00 million-435.00 million vs $430.33 million estimate.

FORR

Forrester Res Affirms FY2024 Adj EPS Guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 Est; Affirms FY2024 Sales Guidance from $425.00M-435.00M to $425.00M-435.00M vs $430.33M Est.

Analyst Daniel Brennan of TD Cowen maintained a Hold rating on 10x Genomics (TXG – Research Report), retaining the price target of $18.00. Daniel B...

10x Genomics: Balancing Market Challenges and Strategic Opportunities

In a report released yesterday, Patrick B Donnelly from Citi maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target o...

Resilient Growth Prospects Amid Challenges: Patrick B Donnelly's Buy Rating on 10x Genomics

10x Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Puneet Souda from Le...

10x Genomics: Buy Rating Amid Short-term Disruptions and Long-term Growth Prospects

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report). The co...

Bank of America Securities Sticks to Its Hold Rating for 10x Genomics (TXG)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on 10x Genomics (TXG – Research Report) yesterday and set a price target of $21.00. Th...

Stifel Nicolaus Remains a Buy on 10x Genomics (TXG)

Analyst Tejas Savant of Morgan Stanley maintained a Buy rating on 10x Genomics (TXG – Research Report), reducing the price target to $30.00. Tejas ...

Buy Rating on 10x Genomics: Strategic Restructuring and Long-term Growth Prospects

10X Genomics (TXG) has disclosed a new risk, in the Environmental / Social category. In a noteworthy development for 10X Genomics, CEO Serge Saxono...

10X Genomics CEO Serge Saxonov Initiates Rule 10b5-1 Trading Plan Amid Strategic Financial Maneuvering

10x Genomics (TXG) and French TechBio startup Cure51 announced that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to un...

10x Genomics' Visium HD selected by TechBio startup Cure51

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report), 10x Genomics (TXG –...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), 10x Genomics (TXG) and Bicycle Therapeutics (BCYC)

Barclays analyst Luke Sergott lowered the firm's price target on 10x Genomics (TXG) to $19 from $21 and keeps an Overweight rating on the shares. T...

10x Genomics price target lowered to $19 from $21 at Barclays

BCYC

Press Releases

10x Genomics Reports Second Quarter 2024 Financial Results

10x Genomics Announces Senior Leadership Changes

10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research

Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

10x Genomics Announces Preliminary Select Third Quarter 2024 Results

10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches

10x Genomics Reports Third Quarter 2024 Financial Results

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

10x Genomics

매도 수량

10x Genomics (NASDAQ:TXG) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌